Benzoquinone derivatives and production thereof

ABSTRACT

A novel benzoquinone derivative of the general formula: ##STR1## [wherein R 1  and R 2  are the same or different and each is methyl or methoxy; n is an integer of 0 to 21; m is 0 or 1, Z is a group of the formula:  (wherein R 3  and R 4  are the same or different and each is hydrogen or an alkyl group which may optionally be substituted or, R 3  and R 4  together with the adjacent nitrogen atom form a morpholino group), a group of the formula: --COR 5  (wherein R 5  is an α-amino acid residue or a substituted or unsubstituted glucosamine residue), a group of the formula: ##STR2## (wherein R 6  is a divalent hydrocarbon group of 1 to 3 carbon atoms), a group of the formula: ##STR3## (wherein R 6  has the same meaning as defined above) or a group of the formula: --CH═CH) l  COR 7  (wherein l is an integer of 1 to 4 and R 7  is hydroxy, methoxy or methyl)] has protocollagen-proline hydroxylase inhibiting activity, collagen biosynthesis inhibiting activity and 5-lipoxygenase suppressant activity, and is useful for the prevention and treatment of such diseases as pulmonary fibrosis, hepatocirrhosis, nephrosclerosis, arteriosclerosis, scleroderma, myelofibrosis and chronic arthritis or for the prevention and treatment of asthma, allergic rhinitis, urticaria, etc.

This application is a division of application Ser. No. 484,232, filedApr. 12, 1983 (now U.S. Pat. No. 4,526,719).

This invention relates to novel benzoquinone derivatives havinginhibitory activities of protocollagen-proline hydroxylase, collagenbiosynthesis and 5-lipoxygenase.

Protocollagen proline hydroxylase is an enzyme which specificallyhydroxylates the proline residues of the protocollagen synthesized byribosomes in animal cells and is one of the important rate-determinantfactors in collagen biosynthesis. Heretofore-known inhibitors of thisenzyme activity include ferrous or ferric chelating agents (e.g.α,α'-dipyridyl, etc.). SH enzyme inhibitors (e.g. p-chloromercurybenzoate, etc.) and certain heavy metals (e.g. Cu⁺⁺, Zn⁺⁺, etc.).However, since these substances entail major side effects as theyinvariably cause a nonspecific inhibition of biosynthesis of collagenand non-collagen proteins, none of them could be used as apharmaceutical product. It follows, therefore, that development of asubstance that will specifically inhibit collagen biosynthesis withoutinhibiting the biosynthesis of other non-collagen proteins at all, thesubstance would be useful for the prevention and treatment of organfibrosis and other diseases which may be caused by an excessiveaccumulation of collagen such as arteriosclerosis, hepatocirrhosis,scleroderma, keloid, rheumatoid arthritis and pulmonary fibrosis.

The present inventors explored the possibility of developing a substancethat may inhibit protocollagen proline hydroxylase activity and foundthat such an inhibitory activity resides in novel benzoquinonederivatives which are represented by the general formula ##STR4##[wherein R₁ and R₂ are the same or different and each is methyl ormethoxy; n is an integer of 0 to 21; m is 0 or 1, Z is a group of theformula: ##STR5## (wherein R₃ and R₄ are the same or different and eachis hydrogen or an alkyl group which may optionally be substituted or, R₃and R₄ together with the adjacent nitrogen atom form a morpholinogroup), a group of the formula: --COR₅ (wherein R₅ is an α-amino acidresidue or a substituted or unsubstituted glucosamine residue), a groupof the formula: ##STR6## (wherein R₆ is a divalent hydrocarbon group of1 to 3 carbon atoms), a group of the formula: ##STR7## (wherein R₆ hasthe same meaning as defined above) or a group of the formula:--CH═CH)_(l) COR₇ (wherein l is an integer of 1 to 4 and R₇ is hydroxy,methoxy or methyl)]. It was also found that these compounds suppressproduction of slow reacting substance of anaphylaxis (hereafter briefly,SRS-A) as well. These findings have resulted in the present invention.

This invention is therefore directed to benzoquinone derivatives ofgeneral formula (I).

In the above general formula (I), the alkyl group which may optionallybe substituted as designated by R₃, R₄ in the group ##STR8## is a C₁₋₄alkyl group (e.g. methyl, ethyl, propyl) which may be substituted byhalogen (Cl, Br, etc.), nitro, amino, hydroxy, etc. The α-amino acidresidue R₅ in the group Z{COR₅ } is the one which has 2 to 11 carbonatoms and is obtainable by removal of one hydrogen atom from the α-aminogroup of an α-amino acid which is exemplified by glycine, alanine,proline, phenylalanine, glutamic acid, methionine, tyrosine, arginine,thioproline, tryptophan, lysine, valine, histidine, leucine, isoleucine,serine, threnonine, cysteine, aspartic acid, oxyproline, etc. Theglucosamine residue which may optionally be substituted as designated byR₅ is a group obtainable after removal of one hydrogen atom from eitherthe amino group or the hydroxy group of glucosamine, and the substituentmay for example be 1-carboxyethyl and may be present in any optionalsubstitutable position of glucosamine. The hydrocarbon residue of 1 to 3carbon atoms as designated by R₆ in the group ##STR9## may for examplebe alkylenes (e.g. methylene, ethylene, propylene etc.), alkenylenes(vinylene, allylene), etc.

The pharmacological actions of compounds (I) according to this inventionare described hereinafter.

(1) Inhibitory activity of protocollagen-proline hydroxylase

Determination of this inhibitory activity was made by the method of R.E. Rhoads et al. [Methods in Enzymology XVII B, 306 (1971)] using apartially purified enzyme preparation obtained from chick embryos inaccordance with the methods of K. I. Kivirriko et al. and J. Halme etal. [J. Biol, Chem. 242, 4007 (1967) and Biochim. Biophys. Acta 198, 460(1967)] and, as a substrate, (Pro-Pro-Gly)₅.4H₂ O [prepared by theProtein Research Foundation, Osaka]. In this procedure, the partiallypurified enzyme was used in an amount of 100 μg as protein.

                  TABLE 1                                                         ______________________________________                                        Compound (I')                                                                  ##STR10##               (μM)trationConcen-                                                                  (%)tionInhibi-                              ______________________________________                                        m:0, n:2, Z:COGly       20       46                                           m:0, n:2, Z:COPro       20       35                                           m:0, n:2, Z:COAla       20       32                                           m:0, n:9, Z:COPhe       20       35                                           m:0, n:9, Z:COGlu       20       37                                           m:0, n:9, Z:COMurNAc    20       32                                           m:0, n:9, Z:COGlcN      20       52                                           m:0, n:2, Z:COGlu       20       20                                           m:0, n:2, Z:CO abm4 Tyr 20       35                                           m:0, n:2, Z:COArg (salt of acetic acid)                                                               20       56                                            ##STR11##              20       35                                           m:0, n:9, Z:COArg (salt of acetic acid)                                                               20       52                                           m:0, n:9, Z:COMet       20       38                                           m:0, n:9, Z:COTrp       20       15                                           m:0, n:9, Z:COLys       20       25                                           m:0, n:9, Z:COHis       20       52                                            ##STR12##              20       78                                            ##STR13##              25       30                                            ##STR14##              25       70                                            ##STR15##              20       82                                            ##STR16##              50 20 10 94 55 39                                      ##STR17##              50 20 10 83 52 43                                      ##STR18##              50 20 10 5 2.5                                                                         100 100 99, 94 72 62                          ##STR19##              50 20 10 92 48 34                                      ##STR20##              50 20 10 5 2.5                                                                         100 100 100, 82 74 64                         ##STR21##              50 20 10 5 2.5                                                                         100 100 100, 92 75 70                         ##STR22##              50 20 10 76 67 38                                      ##STR23##              50 20 10 84 76 54                                      ##STR24##              50 20 10 5 2.5                                                                         68 46  37 22 0                                ##STR25##              50 20 10 5 2.5                                                                         92 92 85 72 51                               ______________________________________                                    

Where

Gly: glycyl

Ala: alanyl

Glu: glutamyl

Arg: arginyl

Lys: lysyl

Met: methionyl

GlcN: glucosamine residue ##STR26## Pro: prolyl Phe: phenylalanyl

Thr: tyrosyl

His: histidyl

MurNAc: N-acetyl muramic acid residue ##STR27##

(2) Inhibitory activity of collagen biosynthesis

In accordance with the method of R. A. Salvador et al. [Arch. Biochem.Biophys. 174, 382 (1976)], 0.2 mg/kg of each test compound wasintraperitoneally administered to SD strain rats (♀, 3 weeks old) once aday for 6 days. After that, the collagen content of the uterus wasdetermined and compared with that of control experiment.

                                      TABLE 2                                     __________________________________________________________________________    Test compound                                                                  ##STR28##                  (g)of rats*Body weight                                                               (mg)of uterusCollagen                                                                  (%)inhibition**Degree             __________________________________________________________________________                                               of                                 (A)                                                                              Control                 73 ± 6                                                                            1.64 ± 0.3                                                                          --                                 (B)                                                                              17β-estradiol      73 ± 3                                                                            3.45 ± 0.11                                                                         --                                 (C)                                                                              17β-estradiol      71 ± 5                                                                            2.86 ± 0.75                                                                         33                                    + Compound of formula (I")                                                    (n: 9, Z: CONHArg)                                                            17β-estradiol      68 ± 3                                                                            2.53 ± 0.28                                                                         51                                    + Compound of formula (I")                                                     ##STR29##                                                                    17β-estradiol      69 ± 6                                                                            2.98 ± 0.15                                                                         26                                    + Compound of formula (I")                                                     ##STR30##                                                                    17β-estradiol      67 ± 3                                                                            2.77 ± 0.25                                                                         38                                    + Compound of formula (I")                                                     ##STR31##                                                                 __________________________________________________________________________     *Rats were used 3 animals as one group; initial body weights 41 ± 2 -      42 ± 4 g.                                                                  ##STR32##                                                                

(3) Inhibition of 5-lipoxygenase activity in RBL-1 cells

10⁷ RBL-1 cells (rat basophilic leukemia cells) are suspended in 0.5 mlof MCM (mast cell medium), and, then, a test solution (0.5 ml of MCM, 50μg of arachidonic acid, 10 μg of A-23187 and 1 μM or 10 μM of thequinone compound) is added. The reaction is conducted at 37° C. for 20minutes. After completion of the reaction, 4 ml of ethanol including1,4-dimethoxy-2-methyl-3-(3-methoxypropyl)naphthalene are added (0.5μg/ml) are added as an internal reference. After shaking well, themixture is allowed to stand at room temperature for 10 minutes. Then,the mixture was centrifuged (2000 r.p.m./min.) for 10 minutes and thesupernatant is separated. This supernatant is concentrated under reducedpressure to about 200 μl. To the concentrate is added a high performanceliquid chromatography solvent [CH₃ CN(1500):CH₃ OH(500):water(1100):acetic acid(2); pH 5.6 (adjusted with aqueous ammonia)] to make atotal of 1 ml. A 200 μl portion of this solution is taken and 5-HETE(5-hydroxyeicosatetraenoic acid) is assayed by high performance liquidchromatography. The degree of inhibition of 5-HETE production (IE) isexpressed in terms of ##EQU1## where a is the peak height or area aftercorrection with the peak of the internal reference standard in theabsence of the quinone compound and b is the peak height or area aftercorrection with the peak of the internal reference standard in thepresence of the quinone compound.

                  TABLE 3                                                         ______________________________________                                        Test compound                                                                  ##STR33##              1 μM10 μMtest compoundConcentration                                    ofproduction (%)5-HETEInhibition                       ______________________________________                                                               of                                                     R.sub.1 : CH.sub.3 O, R.sub.2 : CH.sub.3 O, m: 0,                                                    72.0     83.1                                           ##STR34##                                                                    R.sub.1 : CH.sub.3 O, R.sub.2 : CH.sub.3 O, m: 1,                                                    76.6     85.8                                           ##STR35##                                                                    R.sub.1 : CH.sub.3 O, R.sub.2 : CH.sub.3 O, m: 0,                                                    73.9     83.5                                           ##STR36##                                                                    R.sub.1 : CH.sub.3 O, R.sub.2 : CH.sub.3 O, m: 1,                                                    72.2     83.3                                           ##STR37##                                                                    R.sub.1 : CH.sub.3 O, R.sub.2 : CH.sub.3, m: 0, n: 0,                                                70.1     81.5                                           ##STR38##                                                                    R.sub.1 : CH.sub.3, R.sub.2 : CH.sub.3, m: 0, n: 0,                                                  63.5     79.2                                           ##STR39##                                                                    (control)(BW755C)      21.8     39.1                                           ##STR40##                                                                    (control)              35.9     39.4                                          ETYA*                                                                         ______________________________________                                         *ETYA: Eicosatetraynoic acid                                             

As mentioned hereinbefore, compounds (I) of this invention haveinhibitory activities of protocollagen-proline hydroxylase collagenbiosynthesis and 5-lipoxygenase. The present compound is low intoxicity, i.e. its LD₅₀ value in rat is more than 500 mg/kg (P.O.).Therefore, these compounds are useful as drugs for the prevention andtreatment of organ fibrosis in mammalian animals (e.g. rabbit, rat,mouse, dog, cat, human), for the prevention and treatment of suchdiseases as plumonary fibrosis, hepatocirrhosis, nephrosclerosis,arteriosclerosis, scleroderma, myelofibrosis and chronic arthritis or asantiallergic drugs in the prevention and treatment of asthma, allergicrhinitis, urticaria, etc.

The compounds (I) of this invention may each be administered orally orotherwise, either as it is or as formulated with appropriatepharmacologically acceptable carriers, excipients or/and diluents, invarious dosage forms such as powders, granules, tablets, capsules,injections, etc. The dosage depends on the kinds of disease, symptoms,subject, route of administration, or dosage forms, but in case ofparenteral administration such as injection, the daily dose as thecompound (I) is about 25 mg to 500 mg (0.5 mg to 10 mg/kg), preferably50 mg to 250 mg (1.0 mg to 5 mg/kg) for adult human, and in case of oraladministration, the daily dose is about 100 mg to 1000 mg (1 mg to 10mg/kg), preferably 250 mg to 500 mg (5 mg to 10 mg/kg) for adult human.

The composition of this invention contains a drug of dosage unit form.The drug of dosage unit form means a drug containing a daily dose of thecompound (I) as described above, or its multiples (up to 4 times), orits measures (down to 1/40), which is in the physically separate unitform suitable for administering as a medicine. Each dosage unitgenerally contains 0.3 mg to 250 mg of the compound (I). Among them, aninjection ampoule preferably contains 0.3 mg to 30 mg, and each of otherforms preferably contains 10 mg to 250 mg of the compound (I).

The compounds of general formula (I) can be produced from a compound ofgeneral formula: ##STR41## [wherein R₁, R₂, m, n and Z have the samemeanings as defined hereinbefore; X is hydrogen or a hydroxy group whichmay optionally be protected; Y is a hydroxy group which may optionallybe protected] by subjecting the compound (II) to oxidation reactioneither directly or, as required, after elimination of the protectivegroup(s).

Referring to the general formula (II), the protective group for hydroxygroup X or Y may be any easily removable group, for example, an alkylgroup of 1 to 4 carbon atoms such as methyl, ethyl, n-propyl, i-propyl,n-butyl, i-butyl, etc., an aralkyl group such as benzyl, etc., an acylgroup such as acetyl, benzoyl, benzylcarbonyl, etc., an acetal groupsuch as α-tetrahydropyranyl, methoxymethyl, etc. or a silyl group suchas trimethylsilyl, etc. Among the protective group of hydroxyl shown byX and Y, aralkyl group can be removed by subjecting the compound (II) tohydrogenolysis in the presence of the catalyst such as palladium,palladium on carbon, platinum, etc., acyl group can be removed bysubjecting the compound (II) to hydrolysis in the presence of a basesuch as potassium hydroxide, sodium hydroxide, potassium carbonate,sodium carbonate, etc., and acetal group and silyl group can be removedby subjecting the compound (II) to hydrolysis in the presence of an acidsuch as hydrochloric acid, sulfuric acid, toluenesulfonic acid,camphanesulfonic acid, etc. When the compound (II) wherein X or Y ishydroxyl protected by alkyl group is subjected to oxidative alkylationby using silver oxide or ammonium cerium (IV) nitrate, the protectivegroup is removed and the compound (II) is oxidized to give a compound(I).

The oxidation reaction may be any types of reactions that will transformphenol to quinone without affecting an alcoholic hydroxy group ordeprotection reaction, and examples of the oxidizing agent includeferric chloride, silver oxide, nitrosodisulfonate, ammonium cerium (IV)nitrate, etc. The oxidizing agent is usually used in an amount of 1 to 3moles per mole of compound (II).

This oxidation reaction is generally conducted in the presence of asuitable solvent. The solvent may be used if it is not susceptible tothe oxidation reaction, thus being exemplified by water, a dilute acidor alkali solution, acetone, ethanol, dioxane, acetonitrile, ether,acetic acid, dimethylformamide, tetrahydrofuran, etc. The reactiontemperature and the rate of this oxidation reaction depend on theoxidizing agent employed. This reaction is generally preferablyconducted at -10 to +25° C. for 0.5 to 5 hours.

The compound (I) thus obtained can be isolated and purified bypurification and separation procedure known per se such asconcentration, concentration under reduced pressure, distillation,distillation under reduced pressure, fractional distillation, pHadjustment, solvent extraction, crystallization, recrystallization,phasic transfer and chromatography.

The compound of general formula (I) in which m is 0 and Z is a group ofthe formula: COR₅, that is a compound of general formula: ##STR42##[wherein the symbols have the same meanings as defined hereinbefore],can also be produced by converting the carboxyl group of a compound ofgeneral formula: ##STR43## [wherein the symbols have the same meaningsas defined hereinbefore] to a reactive derivative and, then, reactingthe same with an α-amino acid which may optionally be protected orglucosamine which may optionally be substituted. The reactive derivativeof carboxyl group may for example be an active ester or an acidanhydride. Examples of said active ester include the cyanomethyl ester,thioglycolic acid ester, p-nitrophenyl ester, 2,4,5-trichlorophenylester, pentachlorophenyl ester, pentafluorophenyl ester,pivalohydroxamic acid ester, N-hydroxyphthalimide ester,N-hydroxysuccinimide ester, N-hydroxy-5-norbornene-2,3-dicarboximideester, 8-hydroxyquinolyl ester,2-hydroxy-1,2-dihydro-1-carbethoxyquinolyl ester, 2-hydroxyphenyl ester,2-hydroxy-4,5-dichlorophenyl ester, 2-hydroxypyridyl ester,2-pyridylthiol ester, 1-hydroxybenzotriazol ester unsubstituted orsubstituted by halogenated methyl or methoxyl, and active esters such asenol esters which are obtainable with the use ofN,N'-dicylohexylcarbodiimide orN-ethyl-5-phenyl-isoxazolium-3-sulfonate.

Preferred examples of said acid anhydride include mixed acid anhydridesand acid amides such as imidazolide, isoxazolide, etc.

When α-amino acid has a group or groups such as hydroxyl, guanyl, thesegroups may be protected. Further, when α-amino acid has two or moreamino groups, the amino group(s) which is not allowed to react with areactive derivative of compound (III) is usually protected. As aprotective groups of the α-amino acid, the protective group which isconventionally used as a protective group in the field of peptide andglucose chemistry.

The substituents of the glucosamine include hydroxyl, amino, etc. Thesegroups may be protected by alkyl (e.g. methyl, ethyl, propyl, etc.) oracyl (e.g. acetyl, etc.).

The reaction between a reactive derivative of compound (III) and anα-amino acid which may optionally be protected or glucosamine which mayoptionally be substituted may be conducted in the presence of an organicbase, if necessary. In this reaction, about 0.8 to 1.2 mole of theα-amino acid is used per one mole of compound (III). Example of the baseincludes triethylamine, N-methylmorpholine, N-ethylmorpholine or1-hydroxybenzotriazole, if necessary. The base is usually used in anamount of 1 to 2 moles per one mole of compound (III). The reaction isgenerally carried out at about 0° C. to about 80° C., and preferablyabout 5° to 50° C. for about one to two days. This reaction may becarried out at a temperature outside the above range, if desired. Thisreaction generally proceeds in a solvent, examples of which includeethers such as tetrahydrofuran, dioxane, etc., esters such as ethylacetate, isoamyl acetate, etc., N-alkylamides such asN,N-dimethylformamide, N-methyl-2-pyrrolidone, N,N-dimethylacetamide,etc., and certain other solvents such as dimethyl sulfoxide,hexamethylphosphoramide, etc.

After completion of the above reaction, the protective group can beremoved by a per se known procedure such as catalytic reduction with theaid of a metal catalyst or hydrolytic elimination with an acid.

The compound (I-a) thus obtained can be isolated and purified bypurification and separation procedure known per se such asconcentration, concentration under reduced pressure, distillation,distillation under reduced pressure, fractional distillation, pHadjustment, solvent extraction, crystallization, recrystallization,phasic transfer and chromatography.

The compound of general formula (II) in which Z is a group of theformula: ##STR44## that is a compound of general formula: ##STR45##[wherein R₈ is hydrogen or a lower alkyl group; the other symbols havethe same meanings as defined hereinbefore], can be produced by reactinga compound of general formula: ##STR46## [wherein R₁, R₂, X, Y, n and mhave the same meanings as defined hereinbefore; A is a halogen atom]with a compound of general formula: ##STR47## [wherein the symbols havethe same meanings as defined hereinbefore] in the presence of a base. Inthe above compound (IV), the halogen atom A may for example be chlorine,bromine or iodine. The base may for example be sodium hydride orpotassium tert-butoxide. The amount of base used in this reaction isusually about one to two moles per one mole of compound (IV). The amountof compound (V) to be contacted with compound (IV) is usually 0.8 to 1.2mole per one mole of compound (IV). This reaction is usually carried outin the presence of a suitable solvent such as dimethylformamide,dimethylsulfoxide, tetrahydrofuran, etc. This reaction is usuallycarried out at about 0° C. to about 100° C. for 30 minutes to 3 hours.

The compound of general formula (II) in which Z is a group of theformula: ##STR48## that is a compound of general formula: ##STR49##[wherein the symbols have the same meanings as defined hereinbefore],can be produced by subjecting a compound of general formula: ##STR50##[wherein the symbols have the same meanings as defined hereinbefore] todehydrative condensation. For this dehydrative condensation, phosphorousoxychloride or phosphorus pentachloride is preferably employed asdehydrating agent. The dehydrating agent is generally used in an amountof 2 to 5 mole per one mole of compound (VI). This reaction is carriedout in the presence or absence of a solvent. Examples of the solventinclude halogenated hydrocarbons (e.g. chloroform, dichloroethane,tetrachloroethane, etc.), aromatic hydrocarbons (e.g. benzene, toluene,xylene, etc.), etc. This reaction is usually carried out at about 60° to150° C. for 1 to 5 hours.

The compound of general formula (II) in which Z is a group of theformula: ##STR51## that is a compound of general formula: ##STR52##[wherein the symbols have the same meanings as defined hereinbefore],can be produced by subjecting an aldehyde compound of general formula:##STR53## [wherein the symbols have the same meanings as definedhereinbefore], to Wittig reaction. That is, in this reaction,phosphonium salt is firstly reacted with a base to give a phosphoraneand then the phosphorane is reacted to a compound (VII) to give acompound (IIc). Examples of the phosphonium salt includecarboxymethylthriphenylphosphonium bromide,carboxymethyltriphenylphosphonium chloride,formylmethyltriphenylphosphonium chloride, etc. Examples of the baseinclude sodium hydroxide, potassium hydroxide, potassium tert-butoxide,etc. The amount of the base is usually 1 to 1.5 mole per one mole of thephosphonium salt. In the second reaction, 1 to 1.5 mole of phosphoraneis usually contacted with one mole of compound (VII). The Wittigreaction is usually carried out in the presence of a solvent such asdiethyl ether, tetrahydrofuran, etc. The reaction temperature may rangefrom 0° C. to the boiling point of the used solvent.

The compound of general formula (II) in which Z is a group of theformula: ##STR54## that is a compound of general formula: ##STR55##[wherein the symbols have the same meanings as defined hereinbefore],can be produced by subjecting a compound of general formula (VII) and acompound of general formula: ##STR56## [wherein all the symbols have themeanings as defined hereinbefore] to Leuckart-Wallach reaction. That is,a compound of the formula (VII) is reacted with a compound of theformula (VIII) in the presence of formic acid to produce a compound ofthe formula (IId). This reaction is carried out in the absence orpresence of a suitable solvent. Examples of the suitable solvent includealcohols such as methanol, ethanol, propanol, butanol, etc. The reactiontemperature is usually 50° to 100° C., preferably 60° C. to 80° C. Thereaction is usually 2 to 5 hours. In this reaction, about 0.8 to 1.2mole of compound (VIII) is contacted with one mole of compound (VII) inthe presence of about 0.8 to 1.2 mole of formic acid.

The same compound (IId) can also be produced by subjecting a compound ofgeneral formula: ##STR57## [wherein the symbols have the same meaningsas defined hereinbefore] to reduction, for example with lithiumaluminium hydride. The amount of lithium aluminium hydride used is about2/3-2 moles per mole of compound (IIe). This reduction reaction isusually carried out in the presence of a solvent. Examples of thesolvent include diethyl ether, tetrahydrofuran, etc. The reactiontemperature ranges from 0° C. to the boiling point of the used solvent.

The compound of formula (I) in which Z is ##STR58## that is a compoundof general formula: ##STR59## [wherein the symbols have the samemeanings as defined above] can also be produced by subjecting a compoundof formula: ##STR60## [wherein the symbols have the same meanings asdefined above] and a compound of the formula (VIII) to Leuckart-Wallachreaction. That is, a compound of the formula (IX) is reacted with acompound of the formula (VIII) in the presence of formic acid to producea compound of the formula (I-b). This reaction is carried out in theabsence or presence of a suitable solvent. Examples of the suitablesolvent include alcohols such as methanol, ethanol, propanol, butanol,etc. The reaction temperature is usually 50° to 100° C., preferably 60°to 80° C. The reaction time is usually 2 to 5 hours. In this reaction,about 0.8 to 1.2 moles of compound (VIII) is contacted with one mole ofcompound (IX) in the presence of about 0.8 to 1.2 mole of formic acid.

The compound (I-b) thus obtained can be isolated and purified bypurification and separation procedure known per se such asconcentration, concentration under reduced pressure, distillation,distillation under reduced pressure, fractional distillation, pHadjustment, solvent extraction, crystallization, recrystallization,phasic transfer and chromatography.

The compound of the formula (IX) can be prepared by oxidizing a compoundof the formula (VII). This reaction is carried out by a manner similarto that of the oxidation reaction of a compound of the formula (II).

EXAMPLE 1

To a solution of p-nitrophenyl3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionate (187 mg, 0.5mmol) and glycine (37 mg, 0.5 mmol) in N,N-dimethylformamide (5 ml) wasadded N-ethylmorpholine (128 μl, 1.0 mmol). The mixture was stirred atroom temperature for 2 days. After completion of the reaction, thesolvent was distilled off under reduced pressure and the residue waschromatographed on a Sephadex, LH20 column (1.5×90 cm, eluent: ethanol).The eluate was evaporated and the residue was crystallized from ethylether to give3-(2,3-dimethoxy-5-methyl-1,4-benzoquinone-6-yl)propionyl-glycine (11mg), melting at 128°-130° C. Rf=0.34 (Chloroform-methanol-acetic acid(18:2:1), silica gel plate) (briefly Rf¹), Rf=0.52 (Ethylacetate-pyridine-acetic acid-water (60:20:6:10, v/v, silica gel plate)(briefly Rf²)

Elemental analysis: Calcd. for C₁₄ H₁₇ NO₇ 0.5H₂ O: C, 52.50; H, 5.66;N, 4.37. Found C, 52.75; H, 5.34; N, 4.29.

EXAMPLE 2

To a solution of p-nitrophenyl3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionate (187 mg, 0.5mmol) and L-alanine (45 mg, 0.5 mmol) in N,N-dimethylformamide (5 ml)was added N-ethylmorpholine (128 μl, 1.0 mmol). The mixture was stirredat room temperature for 2 days. After completion of the reaction, thesolvent was distilled off and the residue was chromatographed on aSephadex LH20 column under the same conditions as above. The eluate wasevaporated to give3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionyl-L-alanine (23mg).

[α]_(D) ²¹ -5.5° (c=0.5, methanol)

Rf¹ =0.48, Rf² =0.66

Elemental analysis: Calcd. for C₁₅ H₁₉ NO₇ : C, 56.42; H, 6.00; N, 4.39.Found: C, 56.52; H, 6.17; N, 4.11.

EXAMPLE 3

To a solution of p-nitrophenyl3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionate (187 mg, 0.5mmol) and L-proline (57 mg, 0.5 mmol) in N,N-dimethylformamide (5 ml)was added N-ethylmorpholine (128 μl, 1.0 mmol). The mixture was stirredat room temperature for 2 days. Thereafter, the reaction mixture wasfurther treated in the same manner as Example 1 to give3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionyl-L-proline (81mg), melting at 131° C.

[α]_(D) ²¹ -38.1° (c=0.5, methanol)

Rf¹ =0.61, Rf² =0.58

Elemental analysis: Calcd. for C₁₇ H₂₁ NO₇ : C, 58.11; H, 6.02; N, 3.99.Found: C, 57.88; H, 6.10; N, 4.24.

EXAMPLE 4

To a solution of p-nitrophenyl3-(2,3-dimethoxy-5-methyl-1,4-benzoquinone-6-yl)propionate (187 mg, 0.5mmol) and N-nitro-L-arginine benzyl ester di-p-toluenesulfonate (327 mg,0.5 mmol) in N,N-dimethylformamide (5 ml) was added triethylamine (0.25ml, 1.7 mmol). The mixture was stirred at room temperature for 15 hours.After completion of the reaction, the solvent was distilled off and theresidue was chromatographed on a column of silica gel (5 g) usingmethanol-chloroform (1:19, v/v) as eluent. The eluate was evaporated andthe residue was dissolved in acetic acid (2 ml). With palladium blackcatalyst (30 mg), the solution was hydrogenated at room temperature for10 hours. After completion of the reaction, the catalyst was removed andthe solvent was distilled off. Methanol (5 ml) was added to the residueand the resulting solution was ice-cooled. A solution of ferric chloride(324 mg, 2 mmol) in water (1 ml) was added and the mixture was stirredfor 15 minutes. The resulting mixture was passed through a column ofAmberlite XAD-2 (3 g) with water to remove the inorganic matter. Elutionwith methanol gave a crude compound, which was then concentrated. Theresidue was chromatographed on a Sephadex LR20 column (1.5×45 cm)[eluent: ethanol-0.1M acetic acid (3:2, v/v)]. The eluate was distilledoff to give3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionyl-L-arginine (37mg).

[α]_(D) ²¹ +7.3° (c=0.5, methanol)

Rf¹ =0.02, Rf² =0.21

Elemental analysis: Calcd. for C₁₈ H₂₆ N₄ O₇.CH₃ COOH: C, 51.06; H,6.43; N, 11.91. Found: C, 51.22; H, 6.39; N, 11.74.

EXAMPLE 5

Using p-nitrophenyl3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionate (187 mg, 0.5mmol) and dibenzyl L-glutamate p-toluenesulfonate (250 mg, 0.5 mmol) andfollowing the procedure of Example 4, there was obtained3-(2,3-dimethoxy-5-methylbenzoquinon-6-yl)propionyl-L-glutamic acid (49mg).

[α]_(D) ²¹ -1.7° (c=0.5, methanol)

Rf¹ =0.22, Rf² =0.49

Elemental analysis: Calcd. for C₁₇ H₂₁ NO₉ : C, 53.26; H, 5.52; N, 3.65.Found C, 53.46; H, 5.51; N, 3.50.

EXAMPLE 6

Using p-nitrophenyl3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionate (187 mg, 0.5mmol) and O-benzyl-L-tyrosine (136 mg, 0.5 mmol) and following theprocedure of Example 4, there was obtained3-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionyl-L-tyrosine (43mg), melting at 170° C.

[α]_(D) ²¹ +20.7° (c=0.5, methanol)

Rf¹ =0.37, Rf² =0.68

Elemental analysis: Calcd. for C₂₁ H₂₃ NO₈ : C, 60.42; H, 5.55; N, 3.36.Found: C, 60.33; H, 5.69; N, 3.47.

EXAMPLE 7

To a solution of10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoic acidN-hydroxy-5-norbornene-2,3-dicarboxyimide ester (1.54 g, 3 mmol) andL-histidine (0.47 g, 3 mmol), in N,N-dimethylformamide (10 ml) was addedtriethylamine (0.42 ml, 3 mmol). The mixture was stirred at roomtemperature for 2 days. After completion of the reaction, the solventwas distilled off and the residue was chromatographed on a Sephadex LH20 column (1.5×90 cm, eluent: ethanol) and the eluate was evaporated togive10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-L-histidine(136 mg).

[α]_(D) ²¹ -5.4° (c=0.5, methanol), Rf² =0.61

Elemental analysis: Calcd. for C₂₅ H₃₅ N₃ O₇ : C, 61.33; H, 7.21; N,8.58. Found: C, 61.41; H, 7.17; N, 8.65.

EXAMPLE 8

To a solution of10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoic acidN-hydroxy-5-norbornene-2,3-dicarboxyimide ester (1.54 g, 3 mmol) andN^(G) -nitro-L-arginine benzyl ester di-p-toluenesulfonate (1.97 g, 3mmol) in N,N-dimethylformamide (10 ml) was added triethylamine (0.84 ml,6 mmol). The mixture was stirred at room temperature for 15 hours. Aftercompletion of the reaction, the residue was chromatographed on a columnof silica gel (20 g) [eluent: methanol-chloroform (1:19, v/v)] and theeluate was evaporated. The residue was dissolved in acetic acid (5 ml)and, the solution was hydrogenated with palladium black (100 mg) at roomtemperature for 10 hours. After completion of the reaction, the solventwas distilled off, the residue was dissolved in methanol (5 ml). Thesolution was oxidized with aqueous ferric chloride (1.95 g, 12 mmol)under ice-cooling for 15 minutes. The reaction mixture was passedthrough on a column of Amberlite XAD-2 (9 g) with water to remove theinorganic matter. Then elution with methanol gave a crude compound. Thesolvent was distilled off and the residue was chromatographed on aSephadex LH20 column [ 1.5×4.5 cm; eluent: ethanol-0.1M acetic acid(3:2, v/v)]. The eluate was evaporated to give10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-L-arginine (920mg).

[α]_(D) ²¹ +6.4° (c=0.5, methanol), Rf¹ =0.03, Rf² =0.27

Elemental analysis: Calcd. for C₂₅ H₄₀ N₄ O₇.CH₃ COOH: C, 57.03; H,7.80; N, 9.85. Found: C, 56.84; H, 8.05; N, 9.62.

EXAMPLE 9

Using 10-(2,3-dimethoxy-5-methyl-1,4-benzoquinone-6-yl)decanoic acidN-hydroxy-5-norbornene-2,3-dicarboxyimide ester (1.54 g, 3 mmol) andL-tryptophan benzyl ester p-toluenesulfonate (1.40 g, 3 mmol) andfollowing the procedure of Example 8, there was obtained10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-L-tryptophan(682 mg)

[α]_(D) ²¹ +4.9° (c=0.5, methanol), Rf¹ =0.87, Rf² =0.85

Elemental analysis: Calcd. for C₃₀ H₃₈ H₃₈ N₂ O₇.1/2H₂ O: C, 65.80; H,7.18; N, 5.12. Found: C, 66.00; H, 7.29; N, 5.17.

EXAMPLE 10

Using 10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoic acidN-hydroxy-5-norbornene-2,3-dicarboxyimide ester (1.54 g, 3 mmol) andN.sup.ε -carbobenzoxy-L-lysine benzyl ester (1.63 g, 3 mmol) andfollowing the procedure of Example 8, there was obtained10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-L-lysine (794mg), melting at 107° C.

[α]_(D) ²¹ -5.8° (c=0.5, methanol), Rf¹ =0.03, Rf² =0.19

Elemental analysis: Calcd. for C₂₅ H₄₀ N₂ O₇.CH₃ COOH.H₂ O: C, 58.05; H,8.30; N, 5.01. Found: C, 57.78; H, 8.29; N, 5.33.

EXAMPLE 11

Glucosamine hydrochloride (863 mg, 4 mmol) was suspended in a mixture ofN,N-dimethylformamide (30 ml) and water (2 ml), followed by addition oftriethylamine (0.56 ml, 4 mmol). Then,10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoic acidN-hydroxy-5-norbornene-2,3-dicarboxyimide ester (3.08 g, 6 mmol) wasadded and the whole mixture was stirred at room temperature for 24hours. After completion of the reaction, the solvent was distilled offand the residue was solidified with ethyl acetate-ethyl ether. The solidmatter was collected by filtration, suspended in water (100 ml),collected by filtration and dissolved again in a small amount ofmethanol. Water was added and the resulting solid matter was collectedby filtration to giveN-[10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl]glucosamine(1.76 g).

Rf=0.78 (water-ethyl acetate-n-butanol-acetic acid=1:1:1:1, v/v; silicagel plate)

[α]_(D) ²² +64.0° (c=0.5, N,N-dimethylformamide)

Elemental analysis: Calcd. for C₂₅ H₃₉ NO₁₀ : C, 58.46; H, 7.66; N,2.73. Found: C, 58.58; H, 7.58; N, 2.77.

EXAMPLE 12

To a solution of p-nitrophenyl10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoate (4.73 g, 10mmol) and D-phenylalanine (1.65 g, 10 mmol) in N,N-dimethylformamide (30ml), was added triethylamine (1.4 ml, 10 mmol). The mixture was stirredat room temperature for 2 days, whereupon the insoluble matter almostdisappeared. The solvent was distilled off under reduced pressure andthe residue was chromatographed on a column of silica gel (100 g). Thecolumn was washed well with chloroform and elution withchloroform-methanol-acetic acid (18:2:1, v/v) gave10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-D-phenylalanine(2.56 g), melting at 96°-98° C., after washing up in the usual way.

[α]_(D) ²⁵ -8.8° (c=0.5, methanol), Rf=0.18 (chloroform-acetone-methanol(10:3:2, v/v, silica gel plate) (hereinafter briefly called Rf³)

Elemental analysis: Calcd. for C₂₈ H₃₇ NO₇ : C, 67.31; H, 7.47; N, 2.80.Found: C, 67.17; H, 7.48; N, 2.83.

EXAMPLE 13

To a solution of p-nitrophenyl10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoate (237 mg, 0.5mmol) and L-methionine (149 mg, 1 mmol) in N,N-dimethylformamide (1 ml)was added triethylamine (0.21 ml, 1.5 mmol). The mixture was stirred atroom temperature for 16 hours. After removal of the solvent, the residuewas dissolved in ethyl acetate (10 ml) and the solution was washed with1N hydrochloric acid (5 ml×3) and saturated aqueous sodium chloride (5ml×3) in that order and dried over anhydrous sodium sulfate. The solventwas then distilled off under reduced pressure and the residue waschromatographed on a column of silica gel (7 g). Elution was carried outwith chloroform-methanol (4:1, v/v) and with chloroform-methanol-aceticacid (32:8:1, v/v) in the order mentioned. The fractions containing thedesired compound were combined and the solvent was distilled off underreduced pressure to give10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-L-methionine(150 mg), melting at 83°-85° C.

[α]_(D) ²⁵ -6.6° (c=0.5, methanol),

Rf¹ =0.79

Elemental analysis: Calcd. for C₂₄ H₃₇ NO₇ S.0.5H₂ O: C, 58.51; H, 7.78;N, 2.84; S, 6.51 Found: C, 58.79; H, 7.88; N, 2.90; S, 6.41.

EXAMPLE 14

Using p-nitrophenyl10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoate (474 mg, 1mmol) and L-thioproline (266 mg, 2 mmol) and following the procedure ofExample 13, there was obtained10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-L-thioproline(150 mg) as an oil.

[α]_(D) ²⁵ -61.2° (c=0.5, methanol), Rf¹ =0.74

Elemental analysis: Calcd. for C₂₄ H₃₃ O₇ NS.0.5H₂ O: C, 58.99; H, 7.01;N, 2.87; S, 6.56. Found: C, 58.65; H, 7.21; N, 2.77; S, 6.54.

EXAMPLE 15

(i) t-Butyloxy-D-isoglutamine benzyl ester (3.70 g, 11 mmol) wasdissolved in trifluoroacetic acid (20 ml) and the solution was stirredat room temperature for 30 minutes. The solvent was then distilled off,ether was added and the solvent was distilled off again under reducedpressure. Petroleum ether was added to the residue to give crystals,which were dried in the presence of sodium hydroxide in a desiccator,giving D-isoglutamine benzyl ester trifluoroacetate. This product wasdissolved in acetonitrile (10 ml) and, under ice-cooling, the solutionwas neutralized with triethylamine. Then, p-nitrophenyl10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoate (4.74 g, 10mmol) was added and the mixture was stirred at room temperature for 16hours. After completion of the reaction, the solvent was distilled offand the residue was dissolved in ethyl acetate (70 ml). The solution waswashed with 5% aqueous solution of sodium bicarbonate (30 ml×3), 1Nhydrochloric acid (30 ml×3) and saturated aqueous sodium chloride (30ml×3) in that order and dried over anhydrous sodium sulfate. The solventwas then distilled off under reduced pressure and the residue wasprecipitated as a gel from ethyl acetate-ethyl ether. The same procedurewas repeated twice to give10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-D-isoglutaminebenzyl ester (3.74 g), melting at 83°-85° C.

[α]_(D) ²⁵ +4.4° (c=0.5, methanol), Rf³ =0.68, Rf=0.33(chloroform-methanol=19:1, v/v, silica gel plate) (briefly Rf⁴)

Elemental analysis: Calcd. for C₃₁ H₄₂ N₂ O₈ : C, 65.24; H, 7.42; N,4.91. Found: C, 65.29; H, 7.36; N, 4.97.

(ii)10-(2,3-Dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-D-isoglutaminebenzyl ester (3.42 g, 6 mmol) was dissolved in methanol (12 ml) and, thesolution was hydrogenated with palladium black at room temperature for 3hours. After completion of the reaction, the solvent was distilled offand the residue was dissolved in methanol (25 ml). A solution of ferricchloride (2.43 g, 15 mmol) in water (5 ml) was added and the mixture wasstirred at room temperature for 10 minutes. The solvent was thendistilled off and the residue was dissolved in ethyl acetate (30 ml),washed with water (15 ml×4) and dried over anhydrous sodium sulfate. Thesolvent was distilled off under reduced pressure and the residue waschromatographed on a silica gel column. Elution with chloroform-methanol(9:1, v/v), chloroform-acetone-methanol (10:3:2, v/v) andchloroform-methanol-acetic acid (18:2:1, v/v) in that order gave a crudeproduct. The product was recrystallized from ethanol-ethylether-petroleum ether to give10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl-D-isoglutamine(1.61 g), melting at 136°-137° C.

[α]_(D) +7.0° (c=0.5, methanol)

Rf¹ =0.47, Rf⁴ =0.09

Elemental analysis: Calcd. for C₂₄ H₃₆ N₂ O₈ : C, 59.98; H, 7.55; N,5.83. Found: C, 59.74; H, 7.57; N, 5.95.

EXAMPLE 16

To a solution of10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoic acid (176 mg,0.5 mmol), diphenylmethyl N-acetyl-1-O-benzyl-α-muraminate (275 mg, 0.5ml) and toluenesulfonic acid (10 mg) in anhydrous pyridine (1 ml) wasadded N,N-dicyclohexylcarbodiimide (206 mg, 1 mmol). The reaction wasconducted at room temperature for 90 minutes. The precipitate wasfiltered off and the solvent was distilled off. The residue was purifiedby preparative silica gel thin layer chromatography usingchloroform-methanol (49:1, v/v) as solvent to give diphenylmethylN-acetyl-1-O-benzyl-6-O-[10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl]-α-muraminate(142 mg) as an oil. Rf⁴ =0.88. This oil (142 mg) was hydrogenated in thepresence of palladium black in acetic acid (5 ml) at room temperaturefor 8 hours. The catalyst was filtered off and the solvent was distilledoff. The residue was dissolved in dioxane (5 ml), a solution of ferricchloride (400 mg) in water (0.5 ml) was added, and the mixture wasstirred at room temperature for 30 minutes. The reaction mixture wasextracted with water (20 ml) and ethyl acetate (20 ml) and the organiclayer was washed with water and dried over anhydrous sodium sulfate. Thesolvent was distilled off and the residue was purified by preparativesilica gel thin layer chromatography (eluent: the solvent system forRf¹). After elution, the portion containing the desired compound wasscraped off and the extracted with methanol. The methanol was distilledoff and the residue was dissolved in ethyl acetate, washed with waterand dried over anhydrous sodium sulfate. The solvent was then distilledoff to giveN-acetyl-6-O-[10-(2,3-dimethoxy-5-methyl-1,4-benzoquinon-6-yl)decanoyl]muraminicacid (104 mg).

[α]_(D) ²¹ +34.4° (c=0.5, ethanol), Rf¹ =0.26

Elemental analysis: Calcd. for C₃₀ H₄₅ NO₁₃.0.5H₂ O: C, 56.59; H, 7.28;N, 2.20. Found: C, 56.52; H, 7.40; N, 2.25.

EXAMPLE 17

Compound 10 (1.72 g, 4 mmol) as obtained in Reference Example 1 and2,6-dicarboxypyridine N-oxide (2.20 g, 21 mmol) were dissolved in 30%aqueous acetonitrile (50 ml) and the solution was stirred underice-cooling. To the mixture was added dropwise an ice-cooled solution ofammonium cerium (IV) nitrate (6.58 g, 12 mmol) in 50% aqueousacetonitrile (30 ml) over 30 minutes and the mixture was stirred underthe same conditinos for 30 minutes and then at room temperature for 30minutes. After completion of the reaction, the insoluble matter wasfiltered off and washed well with ethyl acetate (100 ml). The filtrateand washings were combined and the solvent was distilled off underreduced pressure. The residue was treated with ethyl acetate (150 ml)and water (50 ml) to extract the product therefrom. The organic layerwas washed with aqueous sodium chloride and dried (MgSO₄), and theorganic solvent was distilled off under reduced pressure. The residuewas chromatographed on a silica gel column and elution with ethylacetate-isopropyl ether (1:1) gave4-{4-[6-(2,3-dimethoxy-5-methyl-1,4-benzoquinonyl)]butoxy}cinnamic acid(Compound 1, 1.05 g).

Using the compounds 12, 14, 16, 18, 19, 20 and 21 as obtained inReference Examples 1, 6 and 7 and following the same procedure as above,there were obtained the following compounds 2-8.

Compound 2

4-[4-{6-(2,3-dimethoxy-5-methyl-1,4-benzoquinonyl)}-2-methyl-2-butenoxy]cinnamicacid

Compound 3

4-[6-(2,3-dimethoxy-5-methyl-1,4-benzoquinonyl)]methoxycinnamic acid

Compound 4

4-[4-{6-(2,3-dimethoxy-5-methyl)-1,4-benzoquinonyl)}-2-methyl-2-butenxoy]phenylaceticacid

Compound 5

4-[4-(6-2,3-dimethoxy-5-methyl-1,4-benzoquinonyl)]methoxyphenylaceticacid

Compound 6

2-[4-{6-(2,3-dimethoxy-5-methyl-1,4-benzoquinonyl)}methoxyphenyl]propionicacid

Compound 7

3-[6-(2,3-dimethoxy-5-methyl-1,4-benzoquinonyl)]acrylic acid

Compound 8

1-[6-(2,3-dimethoxy-5-methoxy-1,4- benzoquinonyl)]-3-oxo-1-butene

Table 3 shows the physical properties and constants of the Compounds 1-8described above.

                                      TABLE 3                                     __________________________________________________________________________          Molecular formula                                                             (molecular weight)                                                                         Melting                                                                              EM-390NMR (TMS as internal standard)                Compound                                                                            Elemental analysis                                                                         point (°C.)                                                                   δ value                                       __________________________________________________________________________    1     C.sub.22 H.sub.24 O.sub.7 (400.43)                                                         153˜155° C.                                                             (d.sub.6 -DMSO) 1.4˜2.0 (4H), 1.95 (3H),      Calcd.    C, 65.99; H, 6.04                                                                             2.46 (2H), 3.88 (6H), 4.01 (2H), 6.30               Found     C, 65.92; H, 5.84                                                                             (1H), 6.93 (2H), 7.53 (1H), 7.58 (2H).              2     C.sub.23 H.sub.24 O.sub.7 (412.45)                                                         141˜144° C.                                                             (CDCl.sub.3) 1.86 (3H), 2.01 (3H), 3.27 (2H),       Calcd.    C, 66.98; H, 5.87                                                                             3.98 (6H), 4.40 (2H), 5.39 (1H), 6.29               Found     C, 66.93; H, 5.86                                                                             (1H), 6.88 (2H), 7.48 (2H), 7.74 (1H).              3     C.sub.19 H.sub.18 O.sub.7 (358.35)                                                         190˜192° C.                                                             (d.sub.6 -DMSO) 2.05 (3H), 3.93 (6H), 4.93          Calcd.    C, 63.68; H, 5.06                                                                             (2H), 6.34 (1H), 7.02 (2H), 7.56 (1H),              Found     C, 63.30; H, 5.27                                                                             7.63 (2H).                                          4     C.sub.22 H.sub.24 O.sub.7 (400.43)                                                         92˜94° C.                                                                (CDCl.sub.3) 1.84 (3H), 2.00 (3H), 3.26            Calcd.    C, 65.99; H, 6.04                                                                             (2H), 3.54 (2H), 3.98 (6H), 4.34 (2H),              Found     C, 66.08; H, 6.15                                                                             5.36 (1H), 6.82 (2H), 7.16 (2H), 7.71 (1H).         5     C.sub.18 H.sub.18 O.sub.7 (346.34)                                                         107˜110° C.                                                             (CDCl.sub.3) 2.13 (3H), 3.57 (2H), 3.99             Calcd.    C, 62.42; H, 5.24                                                                             (3H), 4.01 (3H), 4.92 (2H), 6.89                    Found     C, 62.10; H, 5.08                                                                             (2H), 7.22 (2H).                                    6     C.sub.19 H.sub.20 O.sub.7 (360.37)                                                         Oily   (CDCl.sub.3) 1.47 (3H), 2.14 (3H), 3.67             Calcd.    C, 63.33; H, 5.59                                                                      substance                                                                            (1H), 4.02 (6H), 4.93 (2H), 6.8˜              Found     C, 63.43; H, 5.68                                                                             7.4 (4H).                                           7     C.sub.12 H.sub.12 O.sub.6 (252.23)                                                         113˜116° C.                                                             (CDCl.sub.3) 2.20 (3H), 4.02 (6H), 6.78             Calcd.    C, 57.14; H, 4.80                                                                             (1H), 7.66 (1H).                                    Found     C, 56.85; H, 4.84                                                   8     C.sub.13 H.sub.14 O.sub.5 (250.26)                                                         85˜86° C.                                                               (CDCl.sub.3) 2.17 (3H), 2.35 (3H), 4.01             Calcd.    C, 62.39; H, 5.64                                                                             (6H), 6.93 (1H), 7.40 (1H).                         Found     C, 62.19; H, 5.77                                                   __________________________________________________________________________

EXAMPLE 18

2,3-Dimethoxy-5-methyl-1,4-bismethoxymethyloxy-6-(8-methoxycarbonyl-1,3,5,7-octatetraenyl)benzene(0.43 g, 1 mmol) as obtained in Reference Example 4 was dissolved inacetone (5 ml), and 2N sulfuric acid (1 ml) was added. The reaction wasconducted under reflux at 70° C. for an hour. The acetone was distilledoff under reduced pressure and the residue was extracted with ethylacetate (25 ml) and water (10 ml). The ethyl acetate layer wasconcentrated under reduced pressure and the residue was dissolved intetrahydrofuran (5 ml). A 1M aqueous ferric chloride solution (2.0 ml)was added and the mixture was stirred at room temperature for 30minutes. After completion of the reaction, the tetrahydrofuran wasdistilled off under reduced pressure, and the residue was extracted withethyl acetate (50 ml) and water (30 ml) to extract the producttherefrom. The organic layer was washed with aqueous sodium chloride,dried (MgSO₄) and concentrated. The residue was recrystallized fromethyl acetate-isopropyl ether (1:1) to give methyl9-[6-(2,3-dimethoxy-5-methyl-1,4-benzoquinonyl)]-2,4,6,8-nonatetraenoate(0.21 g).

mp. 155°-156° C. δ 2.13(3H), 3.74(3H), 3.99(3H), 4.01(3H), 5.92(1H),6.4-6.7(5H), 7.2-7.5(2H).

Elemental analysis: Calcd. for C₁₉ H₂₀ O₆ (344.37): C, 66.27; H, 5.85.Found: C, 65.98; H, 5.85.

EXAMPLE 19

2-Benzoxazolepropionic acid (0.90 g, 2.44 mmol) obtained in ReferenceExample 5 and silver oxide (AgO, 1.21 g, 9.76 mmol) were suspended indioxane (25 ml) and the suspension was cooled to 10° C. 6N nitric acid(2.44 ml) was added dropwise over 10 minutes. The mixture was stirredunder the same conditions for 30 minutes and the dioxane was distilledoff under reduced pressure. To the residue were added ethyl acetate (50ml) and water (30 ml) and the mixture was filtered with the aid ofCelite to remove the insoluble matter. The ethyl acetate layer waswashed with water and dried (MgSO₄), and the solvent was distilled offunder reduced pressure. The residue was chromatographed on silica gelcolumn using ethyl acetate to give2-[2-{6-(2,3,5-trimethyl-1,4-benzoquinonyl)}benzoxazol-6-yl]propionicacid (0.40 g)

δ 1.58(3H), 2.10(6H), 2.21(3H), 3.89(1H), 7.39(1H), 7.57(1H), 7.82(1H)

Elemental analysis: Calcd. for C₁₉ H₁₇ NO₅ (339.35): C, 67.25; H, 5.05;N, 4.13. Found: C, 67.14; H, 5.22; N, 4.01.

EXAMPLE 20

Silver oxide (15 g) was added to a solution of2,3-dimethoxy-5-methyl-6-morpholinomethylhydroquinone (9 g) as obtainedin Reference Example 8 in ether-dioxane (5:2, 70 ml) and the mixture wasstirred at room temperature for 1.5 hours. The filtrate was treated inthe conventional manner and the residue was recrystallized from ethylacetate-hexane to give2,3-dimethoxy-5-methyl-6-morpholinomethyl-1,4-benzoquinone (4.5 g),melting at 60°-62° C.

Elemental analysis: Calcd. for C₁₄ H₁₉ O₅ N: C, 59.77; H, 6.81; N, 4.98.Found: C, 59.87; H, 6.75; N, 4.80.

A solution of 1% hydrochloric acid in methanol (15 ml) was added to theabove product (1.2 g). After evaporation to dryness, the residue wasrecrystallized from methanol-ether to give the hydrochloride (1.19 g),melting at 155°-164° C.

Elemental alalysis: Calcd. for C₁₄ H₁₉ O₅ N.HCl C, 52.91; H, 6.34; N,4.41. Found: C, 52.80; H, 6.48; N, 4.35.

EXAMPLE 21

6-(9-Formylnonyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (0.9 g) asobtained in Reference Example 9 was added portionwise to a solution ofmorpholine formate (0.43 g) in methanol (5 ml) and the mixture waswarmed at 60°-80° C. for one hour. An additional amount of morpholineformate (0.2 g) was added and the mixture was warmed at the sametemperature for an hour. The reaction mixture was poured into an icewater and extraction was carried out with ethyl acetate. The extract wastreated in the conventinoal manner and the residue was purified bysilica gel column chromatography, elution being carried out withhexane-ethyl acetate (4:1). The eluate was evaporated to dryness and anequimolar amount of hydrochloric acid in methanol was added to theresidue. The methanol was evaporated and the residue was recrystallizedfrom methanol-ether to give6-morpholinodecyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone hydrochloride,melting at 101°-103° C.

Elemental analysis: Calcd. for C₂₃ H₃₇ O₅ N.HCl: C, 62.22; H, 8.13; N,3.16. Found: C, 61.98; H, 8.33; N, 3.03.

EXAMPLE 22

6-(9-Formylnonyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (0.4 g) asobtained in Reference Example 9 was added portionwise to a solution ofdimethylamine formate (0.12 g) in methanol (1 ml) and the mixture waswarmed at 60°-80° C. for 3.5 hours. An additional amount ofdimethylamine formate (0.05 g) was added and thereafter the mixture wasfurther treated in the same manner as in Example 21. The residue wasdissolved in ethyl acetate and a solution of oxalic acid in ethylacetate was added. The crystalline precipitate was collected byfiltration and recrystallized from methanol-ether to give6-dimethylaminodecyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone oxalate.

Elemental analysis: Calcd. for C₂₁ H₃₅ O₄ N.C₂ H₂ O₄ C, 60.63; H, 8.19;N, 3.08. Found: C, 60.43; H, 8.03; N, 3.34.

EXAMPLE 23

Using 6-(4-dimethylaminobutyl)-2,3-dimethoxy-5-methyl-hydroquinone asobtained in Reference Example 10 and following the procedure of Example20, there was obtained6-dimethylaminobutyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone.

The product was dissolved in methanol and to the solution was added asolution of oxalic acid (molar equivalent) in methanol. The mixture wasconcentrated and the product was crystallized from methanol-ether togive oxalic acid ester of6-dimethylaminobutyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone.

δ 1.33-1.90(4H), 2.00(3H), 2.50(2H), 2.85(6H), 3.00-3.20 (2H), 3.95(6H)

EXAMPLE 24

By the same manner as Example 20,2,3-dimethoxy-5-methyl-6-dimethylaminomethylhydroquinone (2 g) obtainedin Reference Example 11 was oxidized with silver oxide. Quinone compoundobtained in the usual way was dissolved in ether (20 ml) and to thissolution was added methanol solution of hydrochloric acid. The mixturewas concentrated to dryness. The residue was recrystallized frommethanol-ether to give2,3-dimethoxy-5-methyl-6-dimethylaminomethyl-1,4-benzoquinonehydrochloride (1.45 g) m.p. 139°-145° C.

Elemental analysis: Calcd. for C₁₂ H₁₇ O₄ N.HCl C, 52.27; H, 6.58; N,5.08. Found: C, 52.06; H, 6.58; N, 4.93.

REFERENCE EXAMPLE 1

(a) A solution of 1,2,3,4-tetramethoxy-5-methyl-6-(4-iodobutyl)benzene(3.94 g, 10 mmol) in dimethylformamide (10 ml) was added to a suspensionof ethyl p-hydroxycinnamate (1.92 g, 10 mmol) and 60% sodium hydride inoil (0.42 g, 10.5 mol) in dimethylformamide (18 ml) at room temperature.The mixture was stirred for 30 minutes. After completion of thereaction, the reaction mixture was extracted by addition of 2% aqueousphosphoric acid (50 ml) and isopropyl ether (50 ml). The extract wasconcentrated and the residue was chromatographed on a silica gel columneluting with isopropyl ether to give ethyl4-[4-(2,3,4,5-tetramethoxy-6-methylphenyl)buthoxy]cinnamate (Compound 9,4.51 g). This ethyl ester (2.00 g, 4.37 mmol) was dissolved in anaqueous tetrahydrofuran-methanol solution (25 ml) and hydrolized withsodium hydroxide (0.35 g, 8.75 mmol). The solution was allowed to standat 50° C. overnight. The reaction mixture was acidified with dilutephosphoric acid and the product was extracted with ethyl acetate. Theorganic layer was dried (MgSO₄) and concentrated under reduced pressure.The residue was recrystallized from ethyl acetate-isopropyl ether togive 4-[4-(2,3,4,5-tetramethoxy-6-methylphenyl)buthoxy]cinnamic acid(Compound 10, 1.78 g).

(b) Using1,2,3,4-tetramethoxy-5-methyl-6-(4-chloro-3-methyl-2-butenyl)benzene andmethyl p-hydroxycinnamate and following the procedure described above,there were obtained methyl4-[4-(2,3,4,5-tetramethoxy-6-methylphenyl)-2-methyl-2-butenyloxy]cinnamate(Compound 11) and4-[4-(2,3,4,5-tetramethoxy-6-methylphenyl)-2-methyl-2-butenyloxy]cinnamicacid (Compound 12).

(c) Using 1,2,3,4-tetramethoxy-5-methyl-6-bromomethylbenzene and methylp-hydroxycinnamate and following the procedure described above, therewere obtained methyl 4-(2,3,4,5-tetramethoxy-6-methylbenzyloxy)cinnamate(Compound 13) and 4-(2,3,4,5-tetramethoxy-6-methylbenzyloxy)cinnamicacid (Compound 14).

(d) Using1,2,3,4-tetramethoxy-5-methyl-6-(4-chloro-3-methyl-2-butenyl)benzene andmethyl p-hydroxyphenylacetate and following the procedure describedabove, there were obtained methyl4-[4-(2,3,4,5-tetramethoxy-6-methylphenyl)-2-methyl-2-butenyloxy]phenylacetate(Compound 15) and4-[4-(2,3,4,5-tetramethoxy-6-methylpheny)-2-methyl-2-butenyloxy]phenylaceticacid (Compound 16).

(e) Using 1,2,3,4-tetramethoxy-5-methyl-6-bromobenzene and methylp-hydroxyphenylacetate and following the procedure described above,there were obtained methyl4-(2,3,4,5-tetramethoxy-6-methylbenzyloxy)phenylacetate (Compound 17)and 4-(2,3,4,5-tetramethoxy-6-methylbenzyloxy)phenylacetic acid(Compound 18).

Table 4 shows their physical and spectral properties of the aboveCompounds 9-18.

                                      TABLE 4                                     __________________________________________________________________________          Molecular formula                                                             (molecular weight)                                                                         Melting                                                                              EM-390NMR (TMS as internal standard)                Compound                                                                            Elemental analysis                                                                         point (°C.)                                                                   δ value                                       __________________________________________________________________________     9    C.sub.26 H.sub.34 O.sub.7 (458.56)                                                         Oily   (CDCl.sub.3) 1.32 (3H), 1.5˜2.0 (4H),                                   2.17 (3H),                                          Calcd.    C, 68.10; H, 7.47                                                                      substance                                                                            2.66 (2H), 3.77 (3H), 3.81 (3H), 3.89               Found     C, 68.05; H, 7.53                                                                             (6H), 4.03 (2H), 4.25 (2H), 6.29 (1H),                                        6.89 (2H), 7.48 (2H), 7.66 (1H).                    10    C.sub.24 H.sub.30 O.sub.7 (430.50)                                                         152˜4° C.                                                               (d.sub.6 -DMSO) 1.4˜2.0 (4H), 2.11 (3H),      Calcd.    C, 66.96; H, 7.02                                                                             2.59 (2H), 3.69 (3H), 3.73 (3H), 3.80               Found     C, 66.99; H, 7.08                                                                             (6H), 4.04 (2H), 6.30 (1H), 6.94 (2H),                                        7.54 (1H), 7.57 (2H).                               11    C.sub.26 H.sub.32 O.sub.7 (456.54)                                                         Oily   (CDCl.sub.3) 1.87 (3H), 2.11 (3H), 3.39 (2H),       Calcd.    C, 68.40; H, 7.06                                                                      substance                                                                            3.77 (9H), 3.88 (6H), 4.40 (2H), 5.47               Found     C, 68.57; H, 7.18                                                                             (1H), 6.27 (1H), 6.88 (2H), 7.43 (2H),                                        7.64 (1H).                                          12    C.sub.25 H.sub.30 O.sub.7 (442.52)                                                         117˜8° C.                                                               (CDCl.sub.3) 1.89 (3H), 2.13 (3H), 3.40             Calcd.    C, 67.86; H, 6.83                                                                             (2H), 3.78 (6H), 3.90 (6H), 4.43 (2H),              Found     C, 68.01; H, 6.84                                                                             5.49 (1H), 6.30 (1H), 6.90 (2H), 7.47                                         (2H), 7.75 (1H).                                    13    C.sub.22 H.sub.26 O.sub.7 (402.45)                                                         98˜99° C.                                                               (CDCl.sub.3) 2.23 (3H), 3.78 (3H), 3.80             Calcd.    C, 65.66; H, 6.51                                                                             (3H), 3.83 (3H), 3.90 (3H), 3.93 (3H),              Found     C, 65.65; H, 6.42                                                                             5.07 (2H), 6.31 (1H), 7.03 (2H), 7.51                                         (2H), 7.69 (1H).                                    14    C.sub.21 H.sub.24 O.sub.7 (388.42)                                                         179˜181° C.                                                             (CDCl.sub.3) 2.26 (3H), 3.81 (3H), 3.83             Calcd.    C, 64.94; H, 6.23                                                                             (3H), 3.91 (3H), 3.94 (3H), 5.08 (2H),              Found     C, 64.89; H, 6.31                                                                             6.33 (1H), 7.05 (2H), 7.55 (2H),                                              7.79 (1H).                                          15    C.sub.25 H.sub.32 O.sub.7 (444.53)                                                         Oily   (CDCl.sub.3  ) 1.87 (3H), 2.12 (3H), 3.39           Calcd.    C, 67.55; H, 7.26                                                                      substance                                                                            (2H), 3.52 (2H), 3.66 (3H), 3.77 (6H),              Found     C, 67.32; H, 7.18                                                                             3.89 (6H), 4.38 (2H), 5.47 (1H),                                              6.83 (2H), 7.16 (2H).                               16    C.sub.24 H.sub.30 O.sub.7 (430.50)                                                         Oily   (CDCl.sub.3) 1.87 (3H), 2.10 (3H),                  Calcd.    C, 66.96; H, 7.02                                                                      substance                                                                            3.38 (2H), 3.53 (2H), 3.77 (6H),                    Found     C, 66.83; H, 7.21                                                                             3.89 (6H), 4.37 (2H), 5.45 (1H),                                              6.83 (2H), 7.16 (2H).                               17    C.sub.21 H.sub.26 O.sub.7 (390.44)                                                         Oily   (CDCl.sub.3) 2.23 (3H), 3.56 (2H), 3.68             Calcd.    C, 64.60; H, 6.71                                                                      substance                                                                            (3H), 3.80 (3H), 3.82 (3H), 3.90                    Found     C, 64.38; H, 6.65                                                                             (3H), 3.93 (3H), 5.00 (2H), 6.98                                              (2H), 7.23 (2H).                                    18    C.sub.20 H.sub.24 O.sub.7 (376.41)                                                         Oily   (CDCl.sub.3) 2.24 (3H), 3.59 (2H),                  Calcd.    C, 63.82; H, 6.43                                                                      substance                                                                            3.81 (3H), 3.83 (3H), 3.91 (3H),                    Found     C, 63.84; H, 6.57                                                                             3.94 (3H), 5.02 (2H), 7.00 (2H),                                              7.25 (2H).                                          __________________________________________________________________________

REFERENCE EXAMPLE 2

4-(2,3,4,5-Tetramethoxy-6-methylbenzyloxy)phenylacetic acid (2.07 g, 5.5mmol) was dissolved in tetrahydrofuran-hexamethylphosphoramide (10:1, 11ml). A solution of lithium diisopropylamide in tetrahydrofuran-hexane(20 ml, 2 equivalents) was cooled to -20° C. and the above-mentionedsolution was added to this solution. The mixture was stirred for 30minutes and then, after addition of methyl iodide (0.85 g, 60 mmol), itwas stirred for 1.5 hours, while the reaction temperature was graduallyraised from -20° C. to 0° C. After completion of the reaction,extraction and isolation conducted in a conventional manner gave2-[4-(2,3,4,5-tetramethoxy-5-methylbenzyloxy)phenyl]propionic acid(Compound 19).

[Oily substance, δ 1.49(3H), 2.23(3H), 3.69(1H), 3.80(3H), 3.82(3H),3.89(3H), 3.92(3H), 5.00(2H), 6.99(2H), 7.28(2H)]

REFERENCE EXAMPLE 3

To a cold solution of2,3-dimethoxy-5-methyl-1,4-bismethoxymethyloxy-6-bromobenzene [oilysubstance, δ 2.34 (3H), 3.57 (3H), 3.64 (3H), 3.84 (6H), 5.01 (2H), 5.09(2H)] (9.00 g, 25.6 mmol) in absolute ether (90 ml) was added a solutionof 15% n-butyllithium in hexane (17.6 ml). The mixture was stirred for30 minutes. Dimethylformamide (9.36 g, 128 mmol) was added and thereaction was continued under the same conditions for 30 minutes. Workingup in a conventional manner gave2,3-dimethoxy-5-methyl-1,4-bismethoxymethyloxy-6-formylbenzene [oilysubstance, δ2.48 (3H), 3.55 (3H), 3.58 (3H), 3.85 (3H), 3.95 (3H), 4.99(2H), 5.13 (2H)]. Yield 80%.

REFERENCE EXAMPLE 4

Trimethylphosphonocrotonate (3.82 g, 18.4 mmol) was dissolved intetrahydrofuran (20 ml). Lithiumdiisopropylamide(tetrahydrofuran-hexane, 1.15 equivalents) was cooled to -20° C. and theabove-mentioned solution was added thereto. To this phosphonoylidesolution was added a solution of the formyl compound (6.00 g, 16.7 mmol)as obtained in Reference Example 3 in tetrahydrofuran (30 ml), and thereaction was conducted under the same conditions for 15 minutes and thencontinued at -20° C. to 0° C. for 30 minutes. Working up in usual mannergave2,3-dimethoxy-5-methyl-1,4-bismethoxymethyloxy-6-(4-methoxycarbonyl-1,3-butadienyl)benzene[oily substance, δ 2.27 (3H), 3.49 (3H), 3.58 (3H), 3.76 (3H), 3.86(3H), 3.88 (3H), 5.04 (4H), 5.95 (1H), 6.90 (1H), 6.96 (1H), 7.3-7.6(1H)]. Yield, 90%. This methyl ester (5.74 g, 15.0 mmol) was reducedwith diisobutylaluminum hydride (hexane solution, 34.1 ml, 60 mmol) inabsolute ether at -70° C. Working up in the usual manner gave2,3-dimethoxy-5-methyl-1,4-bismethoxymethyloxy-6-(5-hydroxy-1,3-pentadienyl)benzene[oily substance, δ 1.62 (1H), 2.24 (3H), 3.50 (3H), 3.57 (3H), 3.87(6H), 4.24 (2H), 5.00 (2H), 5.04 (2H), 5.8-6.1 (1H), 6.35 (1H), 6.5-6.7(1H)]. Yield 97%.

The alcohol compound (4.85 g, 13.7 mmol) prepared as above was dissolvedin methylene chloride and the mixture was oxidized with active manganesedioxide (14.6 g) at room temperature for 2 hours. Working up in usualway gave2,3-dimethoxy-5-methyl-1,4-bismethoxymethyloxy-6-(4-formyl-1,3-butadienyl)benzene[oily substance δ 2.30 (3H), 3.49 (3H), 3.58 (3H), 3.86 (3H), 3.89 (3H),5.06 (4H), 6.23 (1H), 7.0-7.4 (3H), 9.65 (1H)]. Yield 93%.

The dienealdehyde compound (4.50 g, 12.8 mmol) obtained as above wasreacted with trimethylphosphonocrotonatoylide under the same conditionsas described above. Working up in usual way gave2,3-dimethoxy-5-methyl-1,4-bismethoxymethyloxy-6-(8-methoxy-carbonyl-1,3,5,7-octatetraenyl)benzene[mp. 51°-52° C., δ 2.27 (3H), 3.50 (3H), 3.58 (3H), 3.73 (3H), 3.88(6H), 5.03 (2H), 5.05 (2H), 5.88 (1H), 6.2-6.9 (6H), 7.2-7.4 (1H)].Yield 48%.

REFERENCE EXAMPLE 5

2,5-Dimethoxy-3,4,6-trimethylbenzoic acid (m.p. 98°-100° C.) was reactedwith methyl 3-amino-4-hydroxyphenylacetate to give methyl4-hydroxy-3-(2,5-dimethoxy-3,4,6-trimethylbenzoylamino)phenylacetate[m.p. 159°-160° C., δ 2.14 (3H), 2.20 (3H), 2.32 (3H), 3.48 (2H), 3.65(6H), 3.70 (3H), 7.02 (3H), 8.30 (1H), 8.87 (1H)] (11.0 g, 28.4 mmol),which was dehydrated with phosphorus oxychloride (13.1 g) to give methyl2-[6-(2,5-dimethoxy-3,4,6-trimethylphenyl)benzoxazol-6yl]acetate m.p.68°-69° C., δ 2.22 (3H), 2.27 (3H), 3.58 (3H), 3.70 (3H), 3.72 (3H),3.76 (2H), 7.32 (1H), 7.55 (1H), 7.76 (1H)] .

To a solution of tetrabutylammonium hydrogen sulfate (3.40 g, 10 mmol)and sodium hydroxide (0.80 g, 20 mmol) in water (10 ml) were added asolution of the benzoxazole compound (1.85 g, 5.0 mmol) obtained asabove in dichloromethane (10 ml) and methyl iodide (5.68 g, 40 mmol).The mixture was stirred vigorously at room temperature for 4 hours.After the reaction, the dichloromethane layer was separated and thedichloromethane was distilled off under reduced pressure. To the residuewas added isopropyl ether (100 ml) and the insoluble matter was filteredoff. The isopropyl ether was then distilled off under reduced pressureand the residue was chromatographed on a silica gel column, elutionbeing carried out with isopropyl ether-hexane to give the correspondingmethyl benzoxazolepropionate [oily substance 0.86 g, δ 1.57 (3H), 2.20(6H), 2.27 (3H), 3.58 (3H), 3.69 (6H), 3.86 (1H), 7.32 (1H), 7.54 (1H),7.76 (1H)].

This methyl ester compound was hydrolyzed with sodium hydroxide in aconventional manner to give the corresponding benzoxazolepropionic acid[δ 1.59 (3H), 2.19 (3H), 2.21 (3H), 2.27 (3H), 3.57 (3H), 3.68 (3H),3.89 (1H), 7.34 (1H), 7.55 (1H), 7.82 (1H), 10.09 (1H)].

REFERENCE EXAMPLE 6

2,3,4,5-Tetramethoxy-6-methylbenzaldehyde (17.3 g, 72.1 mmol), malonicacid (22.5 g, 216 mmol) and piperidine (1.7 ml) were dissolved inpyridine (50 ml). The reaction was conducted for 5 hours, while thetemperature was gradually raised from 50° C. to 100° C. The solvent wasremoved under reduced pressure. The residue was acidified with 2Nhydrochloric acid, extracted and concentrated. Recrystallization of theproduct from ethyl acetate-isopropyl ether gave1,2,3,4-tetramethoxy-5-methylcinnamic acid (Compound 20, 14.3 g, 70%).m.p. 117°-118° C. δ 2.31 (3H), 3.78 (3H), 3.83 (3H), 3.90 (3H), 3.96(3H), 6.59 (1H), 7.94 (1H), 11.2 (1H).

REFERENCE EXAMPLE 7

To a solution of 2,3,4,5-tetramethoxy-6-methylbenzaldehyde (1.56 g, 6.5mmol) and acetone (1.13 g, 19.5 mmol) in methanol (15 ml) was added 28%methanolic sodium methoxide (1.88 g). The mixture was refluxed for 1.5hours. After completion of the reaction, the mixture was concentratedunder reduced pressure. The residue was chromatographed on a silica gelcolumn elution being carried out with isopropyl ether. The fractionscontaining the desired compound were concentrated to give1,2,3,4-tetramethoxy-5-methyl-6-(3-oxo-1-butenyl)benzene (Compound 21,1.09 g, 60% Oily substance) δ 2.28 (3H), 2.36 (3H), 3.77 (3H), 3.79(3H), 3.89 (3H), 3.95 (3H), 6.70 (1H), 7.57 (1H),

REFERENCE EXAMPLE 8

A solution of 2,3-dimethoxy-5-methyl-1,4-benzohydroquinone (2.2 g), 37%formaldehyde (2.4 ml) and morpholine (2.4 ml) in dioxane (11 ml) wasrefluxed at 100° C. for 2 hours. The reaction mixture was evaporated todryness and the residue was suspended in water. The suspension wasextracted with chloroform and the extract was treated in a conventionalmanner. The residue was recrystallized from ether-hexane to give2,3-dimethoxy-5-methyl-6-morpholinomethylhydroquinone (2.23 g), meltingat 127°-130° C.

Elemental analysis: Calcd. for C₁₄ H₂₁ O₅ N: C, 59.35, H, 7.47; N, 4.94.Found: C, 59.66; H, 7.44; N, 5.00.

REFERENCE EXAMPLE 9

Pyridinium chlorochromate (3.3 g) and sodium acetate (0.5 g) weresuspended in dichloromethane (2.5 ml). To the suspension was added asolution of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone(3.38 g) in dichloromethane (20 ml) at room temperature. The mixture wasstirred for an hour. Then, additional amount of pyridiniumchlorochromate (1 g) and sodium acetate (0.5 g) were added and themixture was stirred for another 1.5 hours. The reaction mixture waspoured into an ice water and the mixture was extracted with ethylacetate. The extract was treated in a conventional manner and theresidue obtained was purified by column chromatography using silica gel.Elution was carried out with dichloroethane-ethyl acetate (9:1) and thenwith carbon tetrachloride-ethyl acetate (9:1), and the eluate wasrecrystallized from ethyl acetate-hexane to give6-(9-formylnonyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (1.3 g),melting at 44.5°-46.5° C.

Elemental analysis: Calcd. for C₁₉ H₂₈ O₅ : C, 67.83; H, 8.39. Found: C,67.73; H, 8.27.

REFERENCE EXAMPLE 10

A suspension of6-(3-carboxypropyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (1 g), zincpowder (1.22 g), pyridine (1 ml) and acetic anhydride (1 ml) was stirredfor 12 hours. The insolubles were filtered off and the filtrate wasevaporated to dryness under reduced pressure. The residue was suspendedin water (20 ml) and the suspension was stirred at room temperature for12 hours. The reaction mixture was extracted ethyl acetate and theextract was treated in a conventional manner. The residue obtained waspurified by column chromatography using silica gel and elution wascarried out with carbon tetrachloride-ethyl acetate (3:2). The eluatewas recrystallized from ethyl acetate-hexane to give4-(2,5-diacetoxy-3,4-dimethoxy-6-methylphenyl)butyric acid (0.5 g) ascolorless needles, melting at 125°-127° C.

Elemental analysis: Calcd. for C₁₇ H₂₂ O₈ : C, 57.62; H, 6.26. Found: C,57.59; H, 6.21.

To this product (0.323 g) was added thionyl chloride (2 ml) and thereaction was conducted at room temperature for one hour and then at 80°C. for one hour. The reaction mixture was evaporated to dryness underreduced pressure to give[6-(3-chloroformylpropyl)-2,3-dimethoxy-5-methylhydroquinone]diacetate.To a solution of this product in benzene (4 ml) was added a solution ofdimethylamine (0.214 g) in benzene (1 ml) and the mixture was stirred atroom temperature for 18 hours. Water was added and the mixture wasextracted with ethyl acetate. The extract was treated in a conventionalmanner to give6-(3-dimethylcarbamoylpropyl)-2,3-dimethoxy-5-methylhydroquinonediacetate. To a solution of this product (0.1 g) in ether (2.5 ml) wasadded lithium-aluminum hydride (31 mg) and with ice-cooling the mixturewas stirred for 1.5 hours. Diluted hydrochloric acid was added and thereaction mixture was washed with ethyl acetate, made weakly alkalinewith sodium hydrogen carbonate and extracted with ethyl acetate. Theextract was treated in the conventional manner to give2,3-dimethoxy-5-methyl-6-(4-dimethylaminobutyl)hydroquinone.

REFERENCE EXAMPLE 11

To a solution of 2,3-dimethoxy-5-methyl-1,4-benzoquinone (7 g) inchloroform was added 10% aqueous sodium hydrosulfite. After completionof reduction reaction, the chloroform layer was treated by theconventional manner to give the hydroquinone compound (6.36 g). To thesolution of the product (1.84 g) in dioxane was added a mixture of 40%dimethylamine (1.2 ml) and 10% formaldehyde (3.3 ml) at 80° C. to 90°C., and the mixture was warmed for 3 hours. After 0.5 ml of the abovedimethylamine and formaldehyde was further added, the mixture was warmedfor additional one hour. The mixture was poured into ice water. Themixture was extracted with chloroform and the chloroform layer wastreated in the usual manner to give2,3-dimethoxy-5-methyl-6-dimethylaminomethylhydroquinone.

What is claimed is:
 1. A compound of the formula ##STR61## wherein R₁and R₂ are the same or different and each is methyl or methoxy; n is aninteger of 0 to 21; m is 0 or 1, and Z is morpholino methyl.
 2. Acompound as claimed in claim 1, wherein m is
 0. 3. A compound as claimedin claim 1, wherein n is
 0. 4. A compound as claimed in claim 1, whereineach of R₁ and R₂ is methoxy.
 5. A compound as claimed in claim 1,wherein n is 0, m is 0 and each of R₁ and R₂ is methoxy.
 6. A compoundas claimed in claim 1, wherein the compound is2,3-dimethoxy-5-methyl-6-(N-morpholino)methyl-1,4-benzoquinone.